These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 25603042)

  • 21. One hundred years of drug regulation: where do we go from here?
    Woosley RL
    Annu Rev Pharmacol Toxicol; 2013; 53():255-73. PubMed ID: 23072378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The FDA may not regulate tobacco products as "drugs" or as "medical devices".
    Merrill RA
    Duke Law J; 1998 Apr; 47(6):1071-94. PubMed ID: 10557545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA'S food ingredient approval process: Safety assurance based on scientific assessment.
    Rulis AM; Levitt JA
    Regul Toxicol Pharmacol; 2009 Feb; 53(1):20-31. PubMed ID: 18983884
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biological products: reporting of biological product deviations in manufacturing. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Nov; 65(216):66621-35. PubMed ID: 11503696
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FDA regulation of stem cell-based products.
    Fink DW
    Science; 2009 Jun; 324(5935):1662-3. PubMed ID: 19556496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Stem cells in Texas: Cowboy culture.
    Cyranoski D
    Nature; 2013 Feb; 494(7436):166-8. PubMed ID: 23407522
    [No Abstract]   [Full Text] [Related]  

  • 29. FDA to vet embryonic stem cells' safety.
    Baker M
    Nature; 2008 Apr; 452(7188):670. PubMed ID: 18401364
    [No Abstract]   [Full Text] [Related]  

  • 30. How drugs are developed and approved by the FDA: current process and future directions.
    Ciociola AA; Cohen LB; Kulkarni P;
    Am J Gastroenterol; 2014 May; 109(5):620-3. PubMed ID: 24796999
    [TBL] [Abstract][Full Text] [Related]  

  • 31. What's next after 50 years of psychiatric drug development: an FDA perspective.
    Laughren TP
    J Clin Psychiatry; 2010 Sep; 71(9):1196-204. PubMed ID: 20923624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory crackdown on stem cell therapy: what would the position be in South Africa?
    Jordaan D
    S Afr Med J; 2012 Mar; 102(4):219-20. PubMed ID: 22464500
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioethics: Tighten up Japan's stem-cell practices.
    Ikegaya H
    Nature; 2012 Sep; 489(7414):33. PubMed ID: 22955600
    [No Abstract]   [Full Text] [Related]  

  • 34. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulatory and scientific issues regarding use of foreign data in support of new drug applications in the United States: an FDA perspective.
    Khin NA; Yang P; Hung HM; Maung-U K; Chen YF; Meeker-O'Connell A; Okwesili P; Yasuda SU; Ball LK; Huang SM; O'Neill RT; Temple R
    Clin Pharmacol Ther; 2013 Aug; 94(2):230-42. PubMed ID: 23588316
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Foreword: stem cell applications and tissue engineering approaches in sports medicine- from bench to bedside.
    Khan W
    J Stem Cells; 2010; 5(4):149-54. PubMed ID: 22314863
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adult stem cell therapies walk the line.
    DeFrancesco L
    Nat Biotechnol; 2012 Aug; 30(8):739-41. PubMed ID: 22871705
    [No Abstract]   [Full Text] [Related]  

  • 38. Texas stem cell rules may impede clinical research.
    Arnold C
    Lancet; 2012 May; 379(9828):1776. PubMed ID: 22586718
    [No Abstract]   [Full Text] [Related]  

  • 39. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 40. FDA reform in Congress: FDA's concerns. Food and Drug Administration.
    James JS
    AIDS Treat News; 1996 Apr; (no 245):5-7. PubMed ID: 11363624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.